+

WO2004029089A3 - Nouvelle cible de l’ angiogenese et utilisations - Google Patents

Nouvelle cible de l’ angiogenese et utilisations Download PDF

Info

Publication number
WO2004029089A3
WO2004029089A3 PCT/FR2003/002810 FR0302810W WO2004029089A3 WO 2004029089 A3 WO2004029089 A3 WO 2004029089A3 FR 0302810 W FR0302810 W FR 0302810W WO 2004029089 A3 WO2004029089 A3 WO 2004029089A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnostic
angiogenesis
therapeutic
field
Prior art date
Application number
PCT/FR2003/002810
Other languages
English (en)
Other versions
WO2004029089A2 (fr
Inventor
Fabien Schweighoffer
Silvere Petit
Emmanuel Valentin
Original Assignee
Exonhit Therapeutics Sa
Fabien Schweighoffer
Silvere Petit
Emmanuel Valentin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa, Fabien Schweighoffer, Silvere Petit, Emmanuel Valentin filed Critical Exonhit Therapeutics Sa
Priority to AU2003299096A priority Critical patent/AU2003299096A1/en
Publication of WO2004029089A2 publication Critical patent/WO2004029089A2/fr
Publication of WO2004029089A3 publication Critical patent/WO2004029089A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente demande concerne le domaine de la biologie et de la santé. Elle concerne plus particulièrement l'identification et la caractérisation fonctionnelle d'une nouvelle protéine impliquée dans les mécanismes de perméabilité vasculaire, d'adhésion cellulaire et d'angiogénèse, ainsi que l'utilisation de cette protéine comme cible thérapeutique, diagnostique ou de criblage, Elle porte également sur des outils utilisables pour la mise en oeuvre de méthodes thérapeutiques, diagnostiques ou de criblage, comme notamment des sondes, anticorps, vecteurs, cellules recombinantes, etc. L'invention est particulièrement utile pour la préparation de composés pharmaceutiques dans le domaine des cancers, de l'angiogenèse, des maladies inflammatoires ou des altérations tissulaires.
PCT/FR2003/002810 2002-09-25 2003-09-24 Nouvelle cible de l’ angiogenese et utilisations WO2004029089A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003299096A AU2003299096A1 (en) 2002-09-25 2003-09-24 Novel angiogenesis target and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0211853A FR2844713A1 (fr) 2002-09-25 2002-09-25 Nouvelle cible de l'angiogenese et utilisations
FR02/11853 2002-09-25

Publications (2)

Publication Number Publication Date
WO2004029089A2 WO2004029089A2 (fr) 2004-04-08
WO2004029089A3 true WO2004029089A3 (fr) 2004-06-17

Family

ID=31970980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002810 WO2004029089A2 (fr) 2002-09-25 2003-09-24 Nouvelle cible de l’ angiogenese et utilisations

Country Status (3)

Country Link
AU (1) AU2003299096A1 (fr)
FR (1) FR2844713A1 (fr)
WO (1) WO2004029089A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001029221A2 (fr) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Nouvelles proteines et polynucleotides codant ces proteines
WO2001090304A2 (fr) * 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002014499A2 (fr) * 2000-08-15 2002-02-21 Immunex Corporation Polypeptides de claudines
WO2002024888A2 (fr) * 2000-09-01 2002-03-28 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
WO2002070539A2 (fr) * 2001-03-05 2002-09-12 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099140A1 (fr) * 2001-06-05 2002-12-12 Exelixis, Inc. Glra utiles en tant que modificateurs de la voie de p53 et methodes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001029221A2 (fr) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Nouvelles proteines et polynucleotides codant ces proteines
WO2001090304A2 (fr) * 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002014499A2 (fr) * 2000-08-15 2002-02-21 Immunex Corporation Polypeptides de claudines
WO2002024888A2 (fr) * 2000-09-01 2002-03-28 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
WO2002070539A2 (fr) * 2001-03-05 2002-09-12 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM EMBL; 29 September 2000 (2000-09-29), XP002250864, Database accession no. AK024551 *
DATABASE GSN GENESEQ; 20 January 2003 (2003-01-20), XP002250865, Database accession no. ABZ11501 *
DATABASE GSP [online] GENESEQ; 24 May 2002 (2002-05-24), XP002272083, Database accession no. ABB90003 *
DATABASE GSP GENESEQ; 20 January 2003 (2003-01-20), XP002250866, Database accession no. ABP69284 *

Also Published As

Publication number Publication date
AU2003299096A1 (en) 2004-04-19
AU2003299096A8 (en) 2004-04-19
WO2004029089A2 (fr) 2004-04-08
FR2844713A1 (fr) 2004-03-26

Similar Documents

Publication Publication Date Title
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2004047728A3 (fr) Compositions et procedes destines au traitement de maladies de nature immune
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2005111627A3 (fr) Procedes et produits associes a l'analyse amelioree de glucides
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2004029093A3 (fr) Anticorps anti-granulocytes chimeres, humains et humainises
WO2005040418A3 (fr) Compositions pour le diagnostic et le traitement de maladies associees a l'expression aberrante des futrins (r-spondins) et/ou wnt
WO2011036445A3 (fr) Polypeptides et leurs utilisations
WO2004006838A3 (fr) Nouvelles kinases
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2001064877A3 (fr) Gene humain de la schizophrenie
WO2021181233A3 (fr) Protéines de fusion et leurs utilisations
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2004024072A3 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
WO2005051988A3 (fr) Compositions et procedes permettant de traiter un lupus erythemateux systemique
WO2001060990A3 (fr) Nouvelles kinases de sphingosine
WO2004015060A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
WO2009016231A3 (fr) Compositions et procédés permettant de détecter des troubles liés à l'histamine
WO2004029089A3 (fr) Nouvelle cible de l’ angiogenese et utilisations
WO2007143578A3 (fr) Protéines de perforine-2
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2004005487A3 (fr) Polynucleotides codant une nouvelle proteine tubuline tyrosine ligase bgs42 specifique aux testicules
WO2001074851A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002083841A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载